Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Go back to Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 4.54 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.54 | 52 Week High | $45.34 | |||
| Open | $4.54 | 52 Week Low | $15.92 | |||
| Day High | $4.54 | P/E | 1.95 | |||
| Day Low | $4.54 | EPS | $2.33 | |||
| Volume | 307 | |||||
